NASDAQ:CGEN Compugen - CGEN News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $0.87 0.00 (0.00%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.85▼$0.8950-Day Range$0.65▼$1.2052-Week Range$0.51▼$3.68Volume439,341 shsAverage Volume603,001 shsMarket Capitalization$75.22 millionP/E RatioN/ADividend YieldN/APrice Target$5.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEN Media Mentions By Week CGEN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGEN News Sentiment▼0.360.70▲Average Medical News Sentiment CGEN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGEN Articles This Week▼42▲CGEN Articles Average Week All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCompugen Ltd. (NASDAQ:CGEN) Receives $6.67 Average Price Target from Analystsamericanbankingnews.com - January 25 at 3:48 AMBrokerages Set Compugen Ltd. (NASDAQ:CGEN) Target Price at $6.67americanbankingnews.com - January 25 at 3:48 AMCompugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overviewfinance.yahoo.com - January 23 at 7:27 AMWhy Shares of Compugen Rose on Thursdayfinance.yahoo.com - January 6 at 8:05 AMCompugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancerfinance.yahoo.com - December 14 at 2:09 AMCompugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patientsfinance.yahoo.com - December 1 at 7:49 PMWhy Shares of Compugen Rose 16.5% on Wednesdayfinance.yahoo.com - November 30 at 5:32 PMWhy Shares of Compugen Jumped 17.86% on Thursdaymsn.com - November 19 at 6:24 PMCompugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT Bispecificfinance.yahoo.com - November 16 at 4:07 PMWhy Compugen Stock Crumbled Todayfinance.yahoo.com - November 15 at 5:51 AMCompugen Reports Third Quarter 2022 Resultsfinance.yahoo.com - November 14 at 12:04 PMSVB Securities Sticks to Its Buy Rating for Compugen (CGEN)markets.businessinsider.com - November 11 at 5:41 AMCompugen to Participate in the Stifel Healthcare Conferencefinance.yahoo.com - November 8 at 11:17 AMCompugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patientsfinance.yahoo.com - November 7 at 11:45 AMCompugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patientsfinance.yahoo.com - November 7 at 11:45 AMCompugen Announces Receipt of Nasdaq Delisting Noticefinance.yahoo.com - November 2 at 7:34 PMCompugen to Present New Clinical Data at ESMO-IOfinance.yahoo.com - October 26 at 8:38 AMCGEN.TA - Compugen Ltd. | Stock Price & Latest News | Reutersreuters.com - October 22 at 10:44 PMComputational Biology Global Market Report 2022: Featuring Accelrys, Certara, Chemical Computing Group, Compugen & Entelos - ResearchAndMarkets.com - Business Wirebusinesswire.com - October 18 at 11:46 PMCGEN.A - Compugen Ltd. (USA) | Stock Price & Latest News | Reutersreuters.com - October 15 at 2:07 PMHead and Neck Cancer Clinical Trial Pipeline: Analysis of 130+ Key Companies Working in the Domain | DelveInsight - GlobeNewswireglobenewswire.com - October 10 at 1:31 PMCompugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022finance.yahoo.com - October 6 at 7:51 AMComputational Biology Global Market Report 2022 - Yahoo Finance UKuk.finance.yahoo.com - September 30 at 3:13 PMCompugen Letter to Shareholders - Yahoo Financefinance.yahoo.com - September 23 at 10:36 AMCompugen Letter to Shareholdersfinance.yahoo.com - September 22 at 9:38 AMCompugen Ltd CGEN Stock Quotemorningstar.com - September 15 at 8:34 PMCompugen Names Alberto Sessa CFO, Effective Nov. 1nasdaq.com - September 12 at 11:59 AMCompugen Announces Appointment of Alberto Sessa as Chief Financial Officerfinance.yahoo.com - September 12 at 11:59 AMShareholders in Compugen (NASDAQ:CGEN) are in the red if they invested a year agofinance.yahoo.com - September 1 at 5:22 PMThese 2 'Perfect' Indicators Say the Bear Market Is Over - InvestorPlaceinvestorplace.com - August 26 at 1:22 AMFILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY COUNCIL - Yahoo Canada Financeca.finance.yahoo.com - August 25 at 12:19 AMCompugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japanfinance.yahoo.com - August 24 at 9:38 AMAnalyst Ratings for Compugen - Benzingabenzinga.com - August 23 at 11:37 PMTruist Securities Maintains Buy Rating for Compugen: Here's What You Need To Knowmarkets.businessinsider.com - August 23 at 6:37 PMAnalyst Ratings for Compugenmarkets.businessinsider.com - August 23 at 6:37 PMCGEN.OQ - Compugen Ltd. (USA) | Stock Price & Latest News | Reutersreuters.com - August 22 at 6:19 PMChemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities - Yahoo Financefinance.yahoo.com - August 12 at 10:49 AMJMP Securities Maintains Market Outperform Rating for Compugen: Here's What You Need To Knowmsn.com - August 8 at 11:07 PMThis Analyst Lowers Price Target On Lyft; Also Check Out Some Other Major PT Changes - Benzingabenzinga.com - August 8 at 5:45 PMCompugen Expands anti-PVRIG COM701 Intellectual Property Portfoliofinance.yahoo.com - August 8 at 5:44 PMCompugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q2 2022 Results - Earnings Call Transcriptseekingalpha.com - August 5 at 10:21 AMCompugen GAAP EPS of -$0.11 beats by $0.01 (NASDAQ:CGEN) - Seeking Alphaseekingalpha.com - August 5 at 5:21 AMCompugen Tops Q2 EPS by 1c By Investing.com - Investing.cominvesting.com - August 4 at 2:20 PMCompugen Tops Q2 EPS by 1c By Investing.com - Investing.com Indiain.investing.com - August 4 at 9:19 AMCompugen Reports Second Quarter 2022 Resultsfinance.yahoo.com - August 4 at 9:19 AMEarnings Preview For Compugen - Benzingabenzinga.com - August 3 at 6:18 PMCompugen Q2 2022 Earnings Preview (NASDAQ:CGEN) - Seeking Alphaseekingalpha.com - August 3 at 1:17 PMCompugen to Release Second Quarter Results on Thursday, August 4, 2022finance.yahoo.com - July 29 at 1:15 AMOne Chart Proves That Tech Stocks Are Due for a Huge Breakout! - Nasdaqnasdaq.com - July 28 at 8:49 AMvTv Therapeutics (VTVT) Appoints Paul Sekhri as President and CEO - StreetInsider.comstreetinsider.com - July 27 at 12:47 PM Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:CGEN) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.